Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · July 17, 2023

Adjuvant Icotinib Treatment Duration and Survival Benefits in Patients With Stage II–IIIA EGFR+ Lung Adenocarcinoma



Additional Info

Randomized phase II adjuvant trial to compare two treatment durations of icotinib (2 years versus 1 year) for stage II-IIIA EGFR-positive lung adenocarcinoma patients (ICOMPARE study)
ESMO Open 2023 Jun 20;8(4)101565, C Lv, R Wang, S Li, S Yan, Y Wang, J Chen, L Wang, Y Liu, Z Guo, J Wang, Y Pei, L Yu, N Wu, F Lu, F Gao, J Chen, Y Liu, X Wang, S Li, B Han, L Zhang, Y Ma, L Ding, Y Wang, X Yuan, Y Yang

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading